- NeuroScientific Biopharmaceuticals (NSB) reports “positive” preliminary results from an animal study for multiple sclerosis
- The study evaluated NSB’s lead drug candidate, EmtinB, across four dose groups in a mouse model, with the drug administered daily for a period of 30 days
- The results displayed a reduction in the severity of the disease, from the onset of symptoms and through to the peak, when compared to untreated controls
- Based on the preliminary results, NeuroScientific says it will progress EmtinB into a larger study, and expects to report a full set of in the second half of 2022
- NeuroScientific Biopharmaceuticals last traded at 17.5 cents on June 14
NeuroScientific Biopharmaceuticals (NSB) has reported “positive” preliminary results for its EmtinB treatment following an animal study for multiple sclerosis.
The clinical-stage drug development company released the results from a “gold standard” animal model trial of multiple sclerosis (MS), which was undertaken by a contract research partner in Canada.
The study evaluated NSB’s lead drug candidate, EmtinB, across four dose groups in a mouse model, with the drug administered daily for a period of 30 days, following the onset of initial symptoms in the mice.
The results showed mice treated with ten milligrams per mouse kilogram (mg/kg) and 20mg/kg doses of EmtinB consistently achieved lower clinical scores. The company explained this indicates a reduction in the severity of the disease, from the onset of symptoms and through to the peak of the disease, when compared to untreated controls.
The treatment was also shown to increase myelin in the models, which is important for the efficient function of nerve cells. The destruction of myelin is thought to contribute to the onset of neurological dysfunction which is associated with MS.
NeuroScientific’s Managing Director and CEO Matt Liddelow said the preliminary results from this are highly encouraging for the development of EmtinB as a treatment for MS.
“In comparison to currently marketed MS therapeutics, EmtinB has the potential to be a disease-modifying treatment option for MS patients with a much more tolerable side-effect profile,” Matt Liddelow said.
Based on the preliminary results, NeuroScientific said it will progress EmtinB into a larger study, and expects to report a full set of results midway through the second half of 2022.
NeuroScientific Biopharmaceuticals last traded at 17.5 cents on June 14.